Condition Directory

Colorectal Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Colorectal Cancer. Browse Colorectal Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced May 21, 2026, 1:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

648

Shown on this page

Local recruiting

113

Local phase groups

The trial list below is retrieved from the live ClinicalTrials.gov search API for Colorectal Cancer. Results on this page are currently sorted by Recently updated.

Showing 1–12 of 648 matching trials for Colorectal Cancer.

Indexed local directory records.

Phase distribution

Phase 1 244

Phase 2 232

Not applicable 117

Phase 3 39

Phase 4 4

Early Phase 1 3

Top locations

New York, New York 149 Houston, Texas 133 Boston, Massachusetts 118 Nashville, Tennessee 115 Los Angeles, California 114 Chicago, Illinois 86

Top sponsors

Memorial Sloan Kettering Cancer Center 25 National Cancer Institute (NCI) 23 Alliance for Clinical Trials in Oncology 22 M.D. Anderson Cancer Center 19 City of Hope Medical Center 12 Dana-Farber Cancer Institute 10

Top therapies

fluorouracil 40 leucovorin calcium 36 oxaliplatin 32 Bevacizumab 26 irinotecan hydrochloride 25 Cetuximab 24

Indexed official records

Open in full search

Conditions: Colorectal Cancer
Interventions: Fruquintinib; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 44
States / cities: Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 34 more

Conditions: Colorectal Cancer, Minimal Residual Disease
Interventions: Cetuximab, Cyclophosphamide, Fludarabine Phosphate, Lymphodepleting Chemotherapy, Rimiducid (AP1903), TROP2-CAR-NK Cells; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Solid Tumor, Adult
Interventions: CT3001, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin); Drug
Lead sponsor: Crossignal Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: CRC, Cancer, Colon Cancer, Colorectal Adenocarcinoma, Colorectal Cancer, Lung Cancer, MESOM, Mesothelioma, Mesothelioma, Malignant, NSCLC, NSCLC, Recurrent, Non Small Cell Lung Cancer, Non-Small Cell Squamous Lung Cancer, Ovarian Cancer, Ovarian Neoplasms, Ovary Cancer, Pancreas Cancer, Pancreatic Neoplasm, Rectal Cancer, Solid Tumor, Adult
Interventions: A2B543, A2B694, xT CDx with HLA-LOH Assay; Biological · Diagnostic Test
Lead sponsor: A2 Biotherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 12
States / cities: Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more

Conditions: Colorectal Cancer, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Solid Tumor
Interventions: ASP5834, panitumumab; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 11
States / cities: Santa Monica, California • Atlanta, Georgia • Jefferson, Louisiana + 8 more

Conditions: Colorectal Cancer
Interventions: Standard of Care, Telisotuzumab Adizutecan; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 21
States / cities: Huntsville, Alabama • Fullerton, California • Los Angeles, California + 17 more

Conditions: Colorectal Cancer
Interventions: 5-Fluorouracil, Bevacizumab, Leucovorin, ONO-4578, Opdivo®, Oxaliplatin; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 11
States / cities: Phoenix, Arizona • Los Angeles, California • Lone Tree, Colorado + 8 more

Conditions: Cholangiocarcinoma, Colorectal Cancer, Gastric Cancers, Pancreatic Cancer
Interventions: BOLD-100 +/- FOLFOX Chemotherapy (Arm VII), BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI); Drug
Lead sponsor: Bold Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Santa Monica, California • Tampa, Florida

Conditions: Adjuvant Chemotherapy, Colorectal Cancer, Fruquintinib, Minimal Residual Disease, Tislelizumab, ctDNA
Interventions: Fruquintinib, Tislelizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colorectal Cancer, Colorectal Cancer Metastatic, Liver Metastases
Interventions: AGEN1423, Balstilimab, Botensilimab, Radiation; Drug · Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Cancer
Interventions: High Cysteine Diet, Low Cysteine Diet; Other
Lead sponsor: Purdue University; Other
Eligibility: 45 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Indianapolis, Indiana • West Lafayette, Indiana

Conditions: Colorectal Cancer
Interventions: adenoma vs no adenoma, colonoscopy vs no colonoscopy, survey and expert panel; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 75 Years and older
Enrollment: 130,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: San Diego, California • West Los Angeles, California

About this Colorectal Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Colorectal Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Colorectal Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Colorectal Cancer clinical trials

Filter and sort this condition

Phase distribution

Top locations

Top sponsors

Top therapies

Indexed official records

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

The Food Environment, Microbial Cysteine Metabolism, and Cancer Disparities

Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study

About this Colorectal Cancer clinical trials directory page